Kyntra Bio to Report First Quarter 2026 Financial Results
Rhea-AI Summary
Kyntra Bio (Nasdaq: KYNB) will report first quarter 2026 financial results on Monday, May 11, 2026 after market close and host a conference call and webcast at 5:00 PM ET.
The management team will present corporate and financial updates, followed by a live Q&A; a replay will be available for a limited time on the company’s Events & Presentations page.
Positive
- None.
Negative
- None.
News Market Reaction – KYNB
In the May 5 session, KYNB declined 1.39%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Earnings date announcement | Neutral | +7.3% | Scheduled Q4 and full-year 2025 results with business update and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history shows the prior earnings-date announcement was followed by a solid positive move, indicating investors previously reacted constructively to scheduling of results and updates.
Recent news for KYNB mixed operational updates, clinical data, and investor events. Notably, an earlier earnings date release on Mar 09, 2026 preceded a 7.31% gain into fourth-quarter and full-year 2025 results. Other items included a Q4/FY2025 earnings report with clinical progress, ASCO GU data, and multiple conference appearances, showing ongoing engagement with both clinical and investor audiences.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.
About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com
